SEC Form 4 · accession 0001209191-17-056193
AGIOS PHARMACEUTICALS, INC. · AGIO
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owner
Scott Biller
Officer — Chief Scientific Officer
Period of report
Oct 4, 2017
Accepted (ET)
Oct 5, 2017 · 6:35 pm EDT
Rule 10b5-1 plan
unknown — predates the checkbox
Issuer CIK
0001439222
Table I — non-derivative securities
| Security | Date | Code | Shares | Price | A/D | Owned after | D/I | Nature of ownership |
|---|---|---|---|---|---|---|---|---|
| Common stockF2 | Oct 4, 2017 | S | 10,470 | $70.00 | D | 0 | I | See footnote |
| Common stock | holding | — | — | — | 6,264 | D |
Table II — derivative securities
No Table II lines on this filing.
Explanation of responses
- F1This sale was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person.
- F2Shares held by a spousal lifetime access trust, of which the reporting person's wife is trustee.